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Abstract  
Background: The National Institute for Health and Care Excellence (NICE) emphasises that cost-
effectiveness is not the only consideration in health technology appraisal and is increasingly explicit 
about other factors considered relevant.  Observing NICE decisions and the evidence considered in 
each appraisal ĂůůŽǁƐƵƐƚŽ ‘ƌĞǀĞĂů ?ŝƚƐ implicit weights. 
 
Objectives: This study aims to investigate the influence of cost-effectiveness and other factors on 
NICE decisions and to investigate whether NICE ?Ɛdecision-making has changed through time. 
 
Methods: We build on and extend the modelling approaches in Devlin and Parkin (2004) and Dakin 
et al (2006).  We ŵŽĚĞůE/ ?ƐĚĞĐŝƐŝŽŶƐĂƐďŝŶĂƌǇĐŚŽŝĐĞƐ Pŝ ?Ğ ?ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐfor or against use 
of a healthcare technology in a specific patient group.  Independent variables comprised: the clinical 
and economic evidence regarding that technology; the characteristics of the patients, disease or 
treatment; and contextual factors affecting the conduct of health technology appraisal.  Data on all 
NICE decisions published by December 2011 were obtained from HTAinSite [www.htainsite.com].   
 
Results:  Cost-effectiveness alone correctly predicted 82% of decisions; few other variables were 
significant and alternative model specifications led to very small variations in model performance.  
The odds of a positive NICE recommendation differed significantly between musculoskeletal disease, 
respiratory disease, cancer and other conditions.  The accuracy with which the model predicted NICE 
recommendations was slightly improved by allowing for end of life criteria, uncertainty, publication 
date, clinical evidence, only treatment, paediatric population, patient group evidence, appraisal 
process, orphan status, innovation and use of probabilistic sensitivity analysis, although these 
variables were not statistically significant.  Although there was a non-significant trend towards more 
recent decisions having a higher chance of a positive recommendation, there is currently no 
evidence that the threshold has changed over time.  The model with highest prediction accuracy 
suggested that a technology costing £40,000 per quality-adjusted life-year (QALY) would have a 50% 
chance of NICE rejection (75% at £52,000/QALY; 25% at £27,000/QALY). 
 
Discussion: Past NICE decisions appear to have been based on a higher threshold than the £20,000-
£30,000/QALY range that is explicitly stated.  However, this finding may reflect consideration of 
other factors that drive a small number of NICE decisions or cannot be easily quantified. 
 
Key words 
Health technology assessment; implicit weights; cost-effectiveness, National Institute for Health and 
Care Excellence (NICE); logistic regression. 
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1. Introduction 
The criteria by which health technology assessment (HTA) agencies make their decisions are of 
importance to healthcare providers and to patients whose eligibility for healthcare services is 
established by its recommendations.  They may also influence technology firms ? investment and 
production decisions regarding current and potential products.  However, although the centralised 
authorities in 23 European countries generally state their criteria ?  “ƚŚĞƌĞ ƌĞŵĂŝŶƐ Ă ůĂĐŬ ŽĨ
transparency around critical elements, such as how multiple factors or criteria are weighed during 
ĐŽŵŵŝƚƚĞĞĚĞůŝďĞƌĂƚŝŽŶƐ ? (Stafinski et al 2011). 
 
In England and Wales, the National Institute of Health and Care Excellence (NICE) is responsible for 
providing guidance on which types of healthcare are to be made available by the National Health 
Service (NHS). The decisions by its appraisal committees have been dominated by new 
pharmaceutical products, but its remit is much wider, also appraising medical devices and now also 
public health and social care.  ůƚŚŽƵŐŚ E/ ?Ɛ ŽǀĞƌĂůů ƌĞŵŝƚ ĂŶĚ ĂŝŵƐ ĂƌĞ ĐůĞĂƌůǇ ĚĞĨŝŶĞĚ ďǇ the 
legislation that established it, NICE has been allowed to develop its methods and processes over 
time and they have become increasingly stable and clear.  However, with respect to their decision-
making criteria, several areas of considerable uncertainty remain. 
 
Rawlins and Culyer (2004) ƐƚĂƚĞƚŚĂƚE/ ?Ɛ main criterion for decision-making is cost-effectiveness 
and that the usual measure of cost-effectiveness to be used is the incremental cost-effectiveness 
ratio (ICER) expressed as the cost per quality-adjusted life-year (QALY) gained.  NICE also states that 
the  ‘ƚŚƌĞƐŚŽůĚ ? ICER that determines whether a technology is considered cost-effective is intended 
to represent the opportunity cost to a fixed-budget NHS in terms of QALYs forgone if the technology 
is adopted (NICE 2013, McCabe et al, 2008).  NICE quantifies ƚŚŝƐ  ‘ƐŚĂĚŽǁ ƉƌŝĐĞ ŽĨ Ă Y>z ?, but, 
rather than characterising a ƐŝŶŐůĞ  ‘ƚŚƌĞƐŚŽůĚ ?, it describes, in loose qualitative terms, ranges that 
affect the probability that a technology will be recommended.  Although different documents give 
slightly different values to these ranges, the most recent and definitive statement by NICE (2013) is 
that: 
1.  “Below a most plausible ICER of £20,000 per QALY gained, the decision to recommend the use 
of a technology is normally based on the cost-effectiveness estimate and the acceptability of a 
ƚĞĐŚŶŽůŽŐǇĂƐĂŶĞĨĨĞĐƚŝǀĞƵƐĞŽĨE,^ƌĞƐŽƵƌĐĞƐ ? ?
2.  “ďŽǀĞ Ă ŵŽƐƚ ƉůĂƵƐŝďůĞ /Z ŽĨ  ? ? ? ? ? ? ? ƉĞƌ Y>z ŐĂŝŶĞĚ ? ũƵĚŐĞŵĞŶƚƐ  ? Q ? ǁŝůů ƐƉĞĐŝĨŝĐĂůůǇ
ƚĂŬĞĂĐĐŽƵŶƚŽĨ ? Q ?ƚŚĞĚĞŐƌĞĞŽĨĐĞƌƚĂŝŶƚǇĂƌŽƵŶĚƚŚĞ/Z ? QǁŚĞƚŚĞƌ ?ƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨƚŚĞ
change in health-related quality of life has been inadequately captured [and] the innovative 
nature of the technology [...whether] the technology meets the criteria for special 
consideration as a 'life-extending treatment at the eŶĚ ŽĨ ůŝĨĞ  ? QĂŶĚ ǁŚĞƚŚĞƌ ƚŚĞƌĞ ĂƌĞ ?
aspects that relate to non-health objectives of the NHS ? ? 
3.  “ƐƚŚĞ /ZŽĨĂŶ ŝŶƚĞƌǀĞŶƚŝŽŶ ŝŶĐƌĞĂƐĞƐ ŝŶ ƚŚĞ  ? ? ? ? ? ? ? ƚŽ   ? ? ? ? ? ?ƌĂŶŐĞ ?ƚŚĞŽŵŵŝƚƚĞĞ ?Ɛ
ũƵĚŐĞŵĞŶƚ ? Q ?ǁŝůůŵĂŬĞĞǆƉůŝĐŝƚƌĞĨĞƌĞŶĐĞƚŽƚŚĞƌĞůĞǀĂŶƚĨĂĐƚŽƌƐůŝƐƚĞĚ[above]. ? 
4.  “ďŽǀĞĂŵŽƐƚƉůĂƵƐŝďůĞ/ZŽĨ ? ? ? ? ? ? ?ƉĞƌY>zŐĂŝŶĞĚ ?ƚŚĞŽŵŵŝƚƚĞĞǁŝůůŶĞĞĚƚŽŝĚĞŶƚŝĨǇ
an increasinŐůǇƐƚƌŽŶŐĞƌĐĂƐĞ ? Q ?ǁŝƚŚƌĞŐĂƌĚƚŽƚŚĞĨĂĐƚŽƌƐůŝƐƚĞĚ ?  
Discussing probabilistic ranges rather than a single threshold enables NICE to have considerable 
discretion over its decisions and minimises debates about the legitimacy of its approach and 
disputes ĂďŽƵƚ ƚŚĞ ƉƌĞĐŝƐĞ ǀĂůƵĞ ƚŚĂƚ ƐƵĐŚ Ă  ‘ƚŚƌĞƐŚŽůĚ ? ƐŚŽƵůĚ ƚĂŬĞ ? ,ŽǁĞǀĞƌ ? ŝƚ ƌĞƐƵůƚƐ ŝŶ
ƵŶĐĞƌƚĂŝŶƚǇĂďŽƵƚǁŚǇƉĂƌƚŝĐƵůĂƌĚĞĐŝƐŝŽŶƐŚĂǀĞďĞĞŶŵĂĚĞ ?ǁŚŝĐŚŝƐŝŵƉŽƌƚĂŶƚĨŽƌĂƐƐĞƐƐŝŶŐE/ ?Ɛ
accountability and for predicting what future decisions might be, which in turn may affect future 
research and development spending on health technologies, amongst other things. Moreover, as 
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noted, NICE considers other decision-making criteria as well as cost-effectiveness.  In addition to 
those detailed above, these include: 
1. Severity of underlying illness: more generous consideration is given to the acceptability of an 
ICER in serious conditions, reflecting societǇ ?s priorities (Rawlins et al, 2010);  
 
2. Stakeholder persuasion: Insights provided by stakeholders (e.g. on the adequacy of measures 
used in trials to reflect symptoms and quality of life; Rawlins et al, 2010; NICE 2008);  
 
3. End of life treatments: the public places special value on treatments that prolong life at the 
end of life, providing that life is of reasonable quality (Rawlins et al, 2010; NICE 2009);  
 
4. Disadvantaged populations: special priority is given to improving the health of the most 
disadvantaged members of the population (Rawlins et al, 2010; NICE 2008);  
 
5. Children: given methodological challenges in assessing quality of life in children, society would 
ƉƌĞĨĞƌƚŽŐŝǀĞ ‘ƚŚĞďĞŶĞĨŝƚŽĨƚŚĞĚŽƵďƚ ? ?ZĂǁůŝŶƐet al 2010).  
The weights attached to these additional criteria are rarely quantified and their importance and 
impact are therefore even more uncertain than cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?ƉŽƐƐŝďůĞĞǆĐĞƉƚŝŽŶŝƐƚŚĞ ‘ĞŶĚ
ŽĨůŝĨĞ ?ĐƌŝƚĞƌŝŽŶ ?ǁŚŝĐŚŝƐĞǆƉůŝĐŝƚůǇƌĞůĂƚĞĚƚŽĂŚŝŐŚĞƌǁĞŝŐŚƚŝŶŐĨŽƌY>zƐĂƚƚŚĞĞŶĚŽĨůŝĨĞ ?ĂůƚŚŽƵŐŚ
the actual weights to be used are not specified.  Culyer (2009) notes: 
 “/ĚŽŶŽƚƚŚŝŶŬE/is very good at weighing qualitative factors explicitly [...] nor is it 
very good at explaining recommendations of technologies with ICERs above the £20k 
threshold [...] There is quite a bit of confusion outside NICE (and possibly within it) 
about the meaning of the threshold range of £20- ? ?Ŭ ? ? 
 
Further, Appleby et al (2009) comment that E/ ?ƐƐƚĂƚĞŵĞŶƚƐ 
 “ ? ?ŵŝǆĂƉƌĞĐŝƐĞƋƵĂŶƚŝĨŝĞĚĐƌŝƚĞƌŝŽŶŽĨĂĐŽƐƚƉĞƌY>zŐĂŝŶĞĚƌĂŶŐĞǁŝƚŚĂŶŝŵƉƌĞĐŝƐĞ
qualitative description of other factors affecting NICE decisions  ? Q ?the way in which 
those other factors are combined with the [cost per QALY gained] range in decision-
ŵĂŬŝŶŐŝƐƵŶĐůĞĂƌ ? ?
 
This paper aims ƚŽĂƐƐĞƐƐƚŚĞŝŵƉĂĐƚŽĨE/ ?ƐĐƌŝƚĞƌŝĂŽŶŝƚƐĚĞĐŝƐŝŽŶ-making in practice and thereby 
estimate the weights implicit within NICE technology appraisal (TA) decisions; these weights could 
be viewed as analogous to multi-criteria decision analysis (MCDA) weights that are implied by the 
deliberative process rather than being specified a priori to drive decisions. This could inform NHS 
patients, health technology industries and the public in England and Wales, and prompt discussion 
ĂďŽƵƚ ǁŚĞƚŚĞƌ ƚŚĞ ŝŵƉůŝĐŝƚ ǁĞŝŐŚƚƐ ƌĞĨůĞĐƚ ƐŽĐŝĞƚǇ ?Ɛ ƉƌĞĨĞƌĞŶĐĞƐ. We investigate empirically the 
effect of cost-effectiveness evidence and other factors on the likelihood of NICE recommending a 
technology, using a revealed preference approach to model NICE decision-making. This work builds 
on and extends earlier studies by Devlin and Parkin (2004) and Dakin et al (2006); in particular, the 
much larger number of decisions now available facilitates exploration of the additional research 
questions detailed in Section 2. 
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2. Modelling NICE decision-making 
The economic theory underlying this study comprises the implied values approach, whereby 
decisions are assumed to be based on an objective function that can be analysed by examining the 
outcomes and parameters of the function, to yield the implied relative weights given to those 
parameters.  More specifically, it uses the revealed preference method, whereby real-world 
decisions are examined to estimate the influence of different factors.  Within mainstream 
economics, revealed preference has predominantly been used to analyse the prices paid for similar, 
but differentiated, goods with respect to the differing levels with which they possess the key 
characteristics of that class of goods.  The weights that are implicitly attached to these 
characteristics are known as hedonic prices (Rosen, 1974) and the principal method by which they 
are estimated is known as hedonic regression.  Our approach draws on that theory, but has a 
somewhat different focus.  We are concerned with factors affecting decisions, not prices; our 
decision-makers are not individual consumers within markets, but agents for public bodies. 
Furthermore, we assume that the underlying rationale for decisions is not necessarily the 
maximisation of consumer's utility (although it might be), but an objective function whose 
maximand is not clearly defined.   
 
Our aim is to explore the role of various decision criteria in decision-making by a public body, 
comprising multiple decision-making committees, each comprising multiple individuals who are 
ƚĂƐŬĞĚƚŽǁĞŝŐŚƚŚĞƐĞƵƉǀŝĂĂ ‘ĚĞůŝďĞƌĂƚŝǀĞƉƌŽĐĞƐƐ ? ?ƵůǇĞƌ ? ? ? ? ? ? ? ? ? ?E/ ? ? ? ? ? ? Such processes 
typically involve both scientific evidence (both context-free and context-sensitive) ĂŶĚ  ‘ĐŽůůŽƋƵŝĂů ?
evidence, which is any other evidence that people use in their decision-making.  The appraisal 
ĐŽŵŵŝƚƚĞĞ ?ƐƌŽůĞŝƐŶŽƚƚŽĞŶƐƵƌĞƚŚĂƚĂŶĞǆƉůŝĐŝƚĚĞĐŝƐŝŽŶ-making formula is correctly applied, but to 
exercise judgment over whatever evidence is available, including that shared with the committee by 
its members.  With respect to the criteria for decision-making, these are equally non-explicit, 
ŝŶǀŽůǀŝŶŐE/ŝŶĂ ‘ƐĞĂƌĐŚ ?ĨŽƌƚŚĞŵďĂƐĞĚŽŶĞǆƉĞƌƚŽƉŝŶŝŽŶ ?ƌĞƐĞĂƌĐŚĂŶĚĂĐĐƵŵƵůĂƚĞĚĞǆƉĞƌŝĞŶĐĞ
(Culyer et al, 2007).  This lack of clarity and deliberate non-explicitness makes it all the more 
important that implicit criteria and value-judgements affecting the spending of public resources are 
exposed for public scrutiny. 
 
This analytical framework has been used in previous studies.  Devlin and Parkin (2004) found that 
cost-effectiveness was the key driver of NICE decisions; while uncertainty and burden of disease 
were also significant.  Dakin et al (2006), characterising NICE ĚĞĐŝƐŝŽŶƐ ĂƐ ǇĞƐ ? ŶŽ ? Žƌ  ‘ƌĞƐƚƌŝĐƚĞĚ ? ?
found significant influences on decisions from cost-effectiveness, clinical evidence, technology type, 
and patient group submissions.   
 
Similar approaches have been used to analyse decisions by other HTA bodies.  Linley and Hughes 
(2012), Mshelia et al (2013) and Harris et al (2008) analysed decisions taken on the use of new 
medicines by the All Wales Medicines Strategy Group, the Scottish Medicines Consortium and the 
Australian Pharmaceutical Benefits Advisory Committee (PBAC), respectively.  Each found that other 
criteria significantly affected decisions, in addition to cost-effectiveness.  In contrast, Tappenden et 
al, (2007) used a stated preference approach to explore the importance of various decision criteria 
to individual members of NICE committees; significant variables included the ICER, uncertainty, 
availability of other therapies, and severity of illness. 
 
The models we use to analyse NICE decision-making predict a binary dependent variable 
representing whether a technology was recommended.  NICE recommendations for whole TAs are 
commonly characterised as a three-ǁĂǇ ĐŚŽŝĐĞ ďĞƚǁĞĞŶ P  ‘ǇĞƐ ? ƚŽ Ăůů ƉĂƚŝĞŶƚƐ ĂŶĚ ƚĞĐŚŶŽůŽŐŝĞƐ
considered within the scope ?  ‘ŶŽ ?ƚŽĂůůƉĂƚŝĞŶƚƐĂŶĚ  ‘ƌĞƐƚƌŝĐƚĞĚ ? Žƌ  ‘ŽƉƚŝŵŝƐĞĚ ? ?E/ ?  ? ? ? ? ?, which 
ŵĞĂŶƐ ‘ǇĞƐ ?ƚŽƐŽŵĞƉĂƚŝĞŶƚƐƵď-groups, and no to others.  Dakin et al (2006) categorised decisions 
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in this manner, although there are important limitations to this approach.  First, the clinical 
evidence, ICERs and other considerations used to inform the decision may be specific to the patient 
sub-ŐƌŽƵƉƐĨŽƌǁŚŽŵƚŚĞƚĞĐŚŶŽůŽŐǇ ŝƐƌĞĐŽŵŵĞŶĚĞĚŽƌƌĞũĞĐƚĞĚ ?   ‘RĞƐƚƌŝĐƚĞĚ ?ĚĞĐŝƐŝŽŶƐalso vary 
considerably in terms of their implications for patient access to new technologies  ?K ?EĞŝůůĂŶĚĞǀůŝŶ
2010).  We therefore sub-divided restricted appraisals into their ĐŽŵƉŽŶĞŶƚ ‘ǇĞƐ ?ĂŶĚ ‘ŶŽ ?ĚĞĐŝƐŝŽŶƐ 
concerning use of a single technology, for a clearly-defined group of patients, to enable us to more 
precisely link the decision to the corresponding evidence considered by NICE.  
 
tĞĐŽŶƐŝĚĞƌĞĚƐĞǀĞƌĂůĂůƚĞƌŶĂƚŝǀĞǁĂǇƐƚŽĐŚĂƌĂĐƚĞƌŝƐĞE/ ?ƐĚĞĐŝƐŝŽŶ-making process and the way 
different sets of considerations might affect the final decision outcome: as a sequential, process 
(Figure 1) and as a single production function (Figure 2).  
 
 
 
 
 
 
 
 
 
Figure 1. A sequential model of NICE decision-making 
 
 
 
Figure 2. A production function model of NICE decision-making 
 
The sequential model suggests that, for each decision, NICE first considers effectiveness evidence 
and then, for those technologies that are effective, goes on to consider cost-effectiveness.  Other 
ĐƌŝƚĞƌŝĂ ?Ğ ?Ő ? ?ƐŽĐŝĂůǀĂůƵĞƐ ? ?ĂĐƚĂƐĂŵŽĚŝĨŝĞƌƚŚĂƚŵĂǇĐĂƵƐĞE/ƚŽƌĞĐŽŵŵĞŶĚĂƚĞĐhnology that 
would otherwise be deemed cost-ineffective by the usual standards.  This model is arguably broadly 
Decision
Yes 
Yes 
No 
No 
No 
Yes 
Effectiveness 
Variables: number, 
size, quality of 
clinical trials  
 
Cost- effectiveness 
Variables: ICER 
KƚŚĞƌĐƌŝƚĞƌŝĂ ? ?ƐŽĐŝĂů
ǀĂůƵĞƐ ? 
Variables: severity; 
end of life, orphan 
drugs; age; disease 
type.  
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ŝŶ ŬĞĞƉŝŶŐ ǁŝƚŚ E/ ?Ɛ ĚĞƐĐƌŝƉƚŝŽŶ ŽĨ ƚŚĞ ǁĂǇ ŝƚ ƚĂŬĞƐ ŽƚŚĞƌ ĐƌŝƚĞƌŝĂ ŝŶƚŽ ĂĐĐŽƵŶƚ ĂůŽŶŐƐŝĚĞ ĐŽƐƚ-
effectiveness (NICE 2008, 2009, 2013).  Qualitative evidence suggests that some committee 
members adopt a two-step approach to decision-making, with clinical effectiveness considered first, 
and cost-effectiveness taken into account only if the technology passes the first hurdle (Williams et 
al, 2007).  
 
However, whilst this model is plausible a priori, in practice it presents some challenges.  We cannot 
observe the decisions at any point other than the final decision outcome, which prevents us from 
modelling the third step directly; and the empirical evidence is that a technology is ineffective is 
likely to perfectly predict rejection by NICE.  
 
ŶĂůƚĞƌŶĂƚŝǀĞŵŽĚĞůĐŽŵƉƌŝƐĞƐĂƐŝŵƉůĞ ‘ƉƌŽĚƵĐƚŝŽŶĨƵŶĐƚŝŽŶ ?ĂƉƉƌŽĂĐŚ ?&ŝŐƵƌĞ ? ? ? NICE seeks and 
combines decision inputs, in terms of clinical and economic evidence.  The inputs enter a production 
ƉƌŽĐĞƐƐ ? ĞŶƚĂŝůŝŶŐ ƚŚĞ ƐǇŶƚŚĞƐŝƐ ĂŶĚ ĞǀĂůƵĂƚŝŽŶ ŽĨ ƚŚĂƚ ĞǀŝĚĞŶĐĞ ? ƵƐŝŶŐ E/ ?Ɛ ĚĞĐŝƐŝŽŶ-making 
procedures.  Such procedures are influenced by: the composition and organisation of appraisal 
committees; methods guides that shape the selection of evidence inputs; available (imperfect) 
information about the opportunity costs in the NHS; and available (imperfect) information on social 
preferences with respect to the prioritisation of particular patient, disease or treatment 
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ?Ğ ?Ő ?ĂƐƐƵŐŐĞƐƚĞĚďǇE/ ?ƐŝƚŝǌĞŶ ?ƐŽƵŶĐŝů ? 
 
All evidence passes through this decision-making process, and the decision output is an observable 
 ‘ǇĞƐ ?Žƌ  ‘ŶŽ ? ŝŶĞĂĐŚĐĂƐĞ ? This model suggests a single regression model, where all influences on 
decisions, including both evidence and decision-making processes, are independent variables.  Due 
to the challenges raised by the sequential model, the model in Figure 2 formed the basis for the 
econometric modelling reported in this paper.  
 
Specifically, our study aimed to address the following research questions: 
 
1. Does the probability of rejection increase with increasing ICER? 
2. Is there empirical support for the sigmoid curve proposed by (Rawlins and Culyer, 2004) 
showing the increase in risk of rejection with increasing ICER, and the  ‘ŝŶĨůĞǆŝŽŶ ƉŽŝŶƚƐ ? Ăƚ
£5,000-£15,000 and £25,000-£35,000/QALY gained?   
3. What impact do the other factors identified by NICE have on the probability of NICE rejection? 
Does NICE take account of factors that they state do not merit special consideration (e.g. 
orphan drugs for rare conditions, (Littlejohns and Rawlins, 2009)? 
4. ,ĂǀĞ E/ ?Ɛ ĚĞĐŝƐŝŽŶƐ ĂŶĚ ?Žƌ ƚŚƌĞƐŚŽůĚ ĐŚĂŶŐĞĚ ŽǀĞƌ ƚŝŵĞ ?For example, NICE statements 
about its cost-effectiveness threshold have evolved in subtle yet important ways over time: 
ĨƌŽŵĂŶ ŝŶŝƚŝĂů  ‘ƵŶǁƌŝƚƚĞŶƌƵůĞ ?ŽĨ  ? ? ? ? ? ? ?, to the threshold as lying in the £20,000-£30,000 
region (NICE, 2005), to an increasing tendency to refer to the threshold as £20,000, with 
exceptions made above (NICE, 2013).  Furthermore, key aspects of NICE TA processes and 
methods have changed during this period, including: dropping the differential discount rate, 
thereby increasing the discount rate for costs and lowering that for QALYs (NICE, 2004); 
introducing the single technology appraisal (STA) process in 2005, in an endeavour to speed 
up decision-making; and, most recently, introducing an explicit process for weighting QALYs 
gained at the end of life (NICE, 2009, 2013). 
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3. Data 
The data for this study were obtained from HTAinSite© (www.htainsite.com) and initially comprised 
all 240 NICE TAs published by 31st December 2011, with the exception of 11 appraisals that were 
terminated before any decision was made (Figure 3).  The conceptual models outlined in the 
previous section were used to select a core set of variables for the first regression model from the 
fields available in HTAinSite (Model 1, Table I).  In addition to the ICER, we captured one variable 
indicating the amount of clinical evidence (Total_pts_in_RCTs) since previous work showed this to be 
important (Dakin et al, 2006) and a variable capturing any temporal trends (Date).  We also included 
one measure of stakeholder involvement (Pt_group_sub), whether the intervention was the only 
treatment for this population, whether the decision concerned children and a crude measure of 
disease severity.  End of life considerations were not included in Model 1 as such data are only 
available since 2009.  Uncertainty around the ICER and innovation were not included in Model 1 due 
to difficulties defining variables that consistently capture these issues.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flow diagram of appraisals included in analysis 
 
Each of the 229 non-terminated TAs was sub-divided into 1-19 component decisions, each 
representing a NICE decision to either recommend or reject a single technology in a specific patient 
population.  Sub-division of each TA inevitably requires a degree of researcher judgement; our 
dataset follows that of HTAinSite, which uses a carefully-documented protocol providing a set of 
principles for making those judgements in a consistent manner.  Using this protocol, data were 
extracted by A? ?analysts, and differences were referred to an advisory panel to resolve.  
 
However, HTAinSite did not provide all the data required for modelling.  A key issue was 
ŝĚĞŶƚŝĨŝĐĂƚŝŽŶ ŽĨ ƚŚĞ  ‘ŵĂŝŶ ? /Z ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ĞĂĐŚ ĚĞĐŝƐŝŽŶ ?  ,dŝŶ^ŝƚĞrecords all ICERs 
mentioned in the TA documentation.  For our analysis, however, stronger value judgements were 
ƌĞƋƵŝƌĞĚƚŽŝĚĞŶƚŝĨǇƚŚĞ ‘ŵĂŝŶ ?/Z ?Ɛ ?ƚŚĂƚĚƌŽǀĞE/ĚĞĐŝƐŝŽŶs.  We developed a set of principles to 
guide our selection of the relevant ICERs (Appendix).  
240 appraisals published by 31
st
 December 2011 
E1: 11 terminated appraisals excluded 
I1: 229 appraisals comprising 775 decisions 
E2: 12 decisions without other restriction 
excluded in line with HTA inSite protocol 
I2: 229 appraisals comprising 763 decisions included 
in EDA and stage 1 models 
 
E3a: 161 decisions based on grounds other 
than cost-effectiveness 
E3b: 75 decisions based on non-quantified [36] 
or non-cost/QALY [39] ICERs 
E3c: 17 decisions based on cost/QALY ICERs 
that could not be obtained 
I3: 190 appraisals comprising 510 decisions included 
in models with ICERs 
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Table I. The core set of variables included in Model 1 
Variable name Coding Definition Justification 
Dependent variable  
Recommendation 0=Not recommended 
1=Recommended 
Whether or not NICE recommended the technology for use in the 
population considered in this decision.* 
Main outcome 
Independent variables  
ICER Numeric: £000s/QALY gained Value of the cost per QALY gained for the technology considered in 
this decision compared with a comparator that NICE considered 
relevant to this decision. The ICER(s) most relevant to each decision 
were extracted for this study (Section 3). 
NICE shŽƵůĚĐŽŶƐŝĚĞƌ “ƚŚĞďƌŽĂĚďĂůĂŶĐĞ
ŽĨĐůŝŶŝĐĂůďĞŶĞĨŝƚƐĂŶĚĐŽƐƚƐ ?ĂŶĚŵĂŬĞ
ĚĞĐŝƐŝŽŶƐďĂƐĞĚŽŶ “ĐůŝŶŝĐĂů
ĞĨĨĞĐƚŝǀĞŶĞƐƐĂŶĚĐŽƐƚĞĨĨĞĐƚŝǀĞŶĞƐƐ ?
(NICE 2008). 
Total_pts_in_RCTs Numeric: number of patients Equals number of randomised controlled trials (RCTs) evaluating 
intervention in this population* (including commercial in confidence 
trials*) multiplied by mean number of patients in each fully reported 
RCT.* 
 “E/ƐŚŽƵůĚŶŽƚƌĞĐŽŵŵĞŶĚĂŶ
ŝŶƚĞƌǀĞŶƚŝŽŶ ? Q ?ŝĨƚŚĞƌĞŝƐ ? Q ?ŶŽƚ
ĞŶŽƵŐŚĞǀŝĚĞŶĐĞ ? ?E/ ? ? ? ? ? ? 
Only_treatment 0=Not only treatment 
1=Only treatment for this 
condition  
Whether the technology (or all of the technologies considered 
within the same appraisal) comprises the only treatment available 
for the condition considered in this decision.* 
Hypothesised that NICE is more likely to 
recommend if no alternatives. 
Children 1=Concerns children 
0=Does not concern children 
Whether the decision concerns use of the treatment in children <18 
years. Based on the age groups field in HTAinSite.* 
Interventions for cŚŝůĚƌĞŶĂƌĞŐŝǀĞŶ ‘ƚŚĞ
ďĞŶĞĨŝƚŽĨƚŚĞĚŽƵďƚ ?ĚƵĞƚŽ
methodological challenges (Rawlins 
2010). 
Pt_group_sub 1=Patient group submitted 
evidence 
0=No patient group 
submission 
Whether any patient groups made a submission to NICE in 
conjunction with the appraisal.* 
Proxy for stakeholder involvement. 
Date Numeric (years) Years elapsed between publication of first NICE appraisal in March 
2000 and publication of this appraisal.* 
Evaluates whether NICE decision-making 
is changing. 
Severity Numeric: disutility scale Mean DALY weight across the diseases considered in the 2004 
Global Burden of Disease study that fall into the relevant main 
disease category (WHO 2004). Severity was modelled in a similar 
way by Linley & Hughes (2012). 
NICE state that they accept higher ICERs 
for serious conditions (Rawlins, 2010). 
* Data taken from HTAinSite (www.htainsite.com). 
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4. Empirical methods 
We modelled NICE decisions using logistic regression, which assesses the effect of explanatory 
variables on the log-odds of success, in this case E/ƐĂǇŝŶŐ ‘ǇĞƐ ?.  Standard errors were adjusted for 
within-appraisal clustering of decisions, since decisions concerning different drugs or patient 
populations within the same appraisal are made by the same committee on the same day and are 
often based on similar or related evidence, so are unlikely to be independent.  All statistical analyses 
were conducted in Stata Version 12 (StataCorp 2011). 
 
For 45% (229/510) of decisions with usable ICERs, we identified A? ? /ZƐ ƚŚĂƚ ŝŶĨŽƌŵĞĚ E/ ?Ɛ
decision-making.  For example, some gave separate ICERs for several patient subgroups considered 
in the same decision or gave equal prominence to two different analyses.  Thirty-one decisions gave 
an ICER range (e.g. stating that the ICER was between X and Y), while others simply said that the ICER 
ǁĂƐ  “ĂďŽǀĞ ?Žƌ  “ďĞůŽǁ ? ? Taking the mean, median or midpoint of the reported ICERs would 
have made assumptions about how NICE used this information in their decision-making.  It would 
ĂůƐŽŚĂǀĞƉƌĞǀĞŶƚĞĚƵƐĨƌŽŵŝŶĐůƵĚŝŶŐĚĞĐŝƐŝŽŶƐǁŝƚŚ/ZƐ “ĂďŽǀĞ ?ĂŶĚǁŽƵůĚŽǀĞƌĞƐƚŝŵĂƚĞƚŚĞ
precision of our regression results by ignoring the uncertainty around the ICER. Instead, we used a 
simulation approach to sample repeatedly from the list of ICERs identified for each decision.  For the 
198 decisions with 2-40 relevant ICERs, the ICER used in each of 100 iterations
1
 was randomly 
sampled by assigning equal probability to all ICERs.  For the 31 cases giving a range or lower/upper 
limit, ICER values were sampled from a list of all ICERs within our dataset that lay in the relevant 
range, since ICERs follow an unknown distribution and may approach infinity (Briggs and Fenn 1998). 
For example, for those decisions for which the Guidance indicateĚ ƚŚĞ /Z ǁĂƐ  “ĂďŽǀĞ
 ? ? ? ? ? ? ? ?Y>z ? ? ǁĞ ĐƌĞĂƚĞĚ Ă ůŝƐƚ ŽĨ Ăůů /ZƐ ƌĞƉŽƌƚĞĚ ŝŶ ŽƚŚĞƌ E/ ĚĞĐŝƐŝŽŶƐ ƚŚĂƚ ǁĞƌĞ
>£30,000/QALY and sampled at random from this list, assigning equal probability to each ICER.  For 
the 281 decisions with one relevant ICER, this single ICER value was used in all 100 datasets.  These 
sampling procedures generated 100 datasets, each with different ICER data for those decisions with 
>1 relevant ICER.  
 
Regression models were run separately on all 100 datasets and results were combined by 
implementing ZƵďŝŶ ?ƐƌƵůĞ ?ĂƌůŝŶet al 2008), which averages parameter estimates (e.g. regression 
coefficients) across multiple imputed datasets and adjusts standard errors to allow for uncertainty 
around the different ICER values.  
 
The primary measure of model performance comprised the proportion of decisions that were 
ĐŽƌƌĞĐƚůǇĐůĂƐƐŝĨŝĞĚ ?ƐŝŶĐĞŝƚ ŝƐŶŽƚǀĂůŝĚƚŽĂƉƉůǇZƵďŝŶ ?ƐƌƵůĞƚŽŵĞĂƐƵƌĞƐŽĨŵŽĚĞůĨŝƚŽƌůŝŬĞůŝŚŽŽĚ ?
such as pseudo-R
2
 ĂŶĚŬĂŝŬĞ ?ƐŝŶĨŽƌŵĂƚŝŽŶĐƌŝƚĞƌŝŽŶ ?/; White et al 2011).  Ideally, the proportion 
of correctly-predicted outcomes would be based on a validation sample independent of the data 
used to estimate the model (Copas, 1983).  Unfortunately, this was not feasible due to the limited 
number of appraisals available; we therefore rely on a single dataset to both estimate and assess 
model performance, which may result in overly optimistic results.  
 
The proportion of NICE decisions correctly predicted, together with the specificity (the proportion of 
rejected decisions predicted as rejected) and sensitivity (the proportion of recommended decisions 
predicted as recommended), ǁĞƌĞ ĐĂůĐƵůĂƚĞĚ ďǇ ĂƐƐƵŵŝŶŐ ƚŚĂƚ Ăůů ĚĞĐŝƐŝŽŶƐ ǁŝƚŚ A? ? ?A? ƉƌĞĚŝĐƚĞĚ
probability of success would be recommended by NICE. Pseudo-R
2
 and AIC calculated from the mean 
log-likelihood for the best models (averaged across all datasets) are also shown for illustration, 
although these figures should be interpreted with caution.  
 
                                                 
1
 ICERs were sampled 100 times to generate 100 datasets to generate robust results capturing the full range ICERs for each 
decision. 
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Our analyses were primarily exploratory and aimed to identify which factors are most influential and 
the best way to input each factor. We therefore explored a wide range of model specifications in a 
series of four stages.  In stages B and C, prediction accuracy was compared between models and the 
model with the highest proportion of decisions correctly classified was taken forward to the next 
stage.  
 
a) Evaluation of Model 1, which included only the seven variables that we predicted to have 
most effect on NICE decisions (Table I).  This model was compared against Model 5, which 
included only the ICER. 
b) Identification of variables explaining NICE decision-making.  We added additional independent 
variables (Table A1) into Model 1 to assess whether they improved prediction accuracy and/or 
had a significant effect on NICE decisions and removed variables from Model 1 one at a time 
to identify which explained NICE decisions.  All the variables that improved prediction 
accuracy when considered individually were then evaluated simultaneously in Model 2.  Those 
variables that were statistically significant in at least one analysis were included in Model 3. 
c) Alternative specifications: We then varied the specification of the variables in Model 2 to 
evaluate the effect that this has on the proportion of decisions that are correctly classified and 
the statistical significance of this parameterisation (see Appendix).  The specification for each 
variable that had highest prediction accuracy when considered individually was included in 
Model 4.  
d) Sensitivity and subgroup analyses: Conducted on Model 4 (see Appendix). 
 
Methods similar to those described by Devlin and Parkin (2004) were used to estimate the ICER at 
which there is a 25%, 50% or 75% chance of a positive NICE recommendation.  The predicted log-
odds of E/ ƐĂǇŝŶŐ  ‘ǇĞƐ ?was calculated for different ICER values by multiplying the vector of 
estimated coefficients by the vector of mean values for other explanatory variables and the ICER 
value of interest.  Similar figures were estimated for particular types of decisions (e.g. those on 
cancer) by repeating calculations using values of zero and one for that dummy variable in place of its 
mean.  
 
Regression analyses included only decisions concerning treatments that are more costly and more 
effective than their comparator.  Decisions for which all relevant ICERs indicated that the technology 
was either dominated or dominant relative to its comparator were excluded from regression 
analyses since dominance perfectly predicted NICE recommendations.  ICERs in the south-west 
quadrant of the cost-effectiveness plane (which indicate that treatment is less costly and less 
effective than its comparator) have the opposite interpretation to those in the north-east quadrant 
(which indicate that treatment is more effective and more costly) and the two types of ICER data 
cannot ĞĂƐŝůǇ ďĞ ĐŽŵďŝŶĞĚ ǁŝƚŚŽƵƚ ŵĂŬŝŶŐ ǀĂůƵĞ ũƵĚŐĞŵĞŶƚƐ ĂďŽƵƚ E/ ?Ɛ ƉƌĞĨĞƌĞŶĐĞƐ ? ǁĞ
therefore also excluded six decisions for which all ICERs lay in the south-west quadrant.  Twenty-two 
decisions had ICERs in >1 quadrant; these decisions were included in regression analyses in those 
datasets where a north-east quadrant ICER was sampled and were dropped from regressions in 
datasets where an ICER from another quadrant was sampled.  As result, the number of decisions 
included in each regression varied between 424 and 432.   
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5. Results 
Our dataset comprised 763 decisions from 229 appraisals (Figure 3). Of these, 253 decisions did not 
report any usable ICERs and were therefore omitted from regression analyses:  
a) Seventy decisions were rejected due to lack of clinical evidence; these decisions had 
significantly fewer patients in RCTs (p<0.001) than other decisions, although 59% (41/70; 
Table II) were nonetheless supported by one or more RCT.  
 
b) Sixty-three decisions were recommended on clinical grounds (e.g. because all alternative 
technologies were contraindicated or not tolerated), while 28 decisions were rejected on 
clinical grounds (e.g. because ƚƌĞĂƚŵĞŶƚǁĂƐ “ĐůŝŶŝĐĂůůǇŝŶĂƉƉƌŽƉƌŝĂƚĞ ?ŝŶƚŚĂƚƉĂƚŝĞŶƚŐƌŽƵƉ).  
The decisions made on clinical grounds were, on average, published two years earlier than the 
average decision based on cost-effectiveness (p<0.001), had less RCT evidence (p=0.006) and 
were more likely to be for children (p<0.001), although the characteristics were otherwise 
similar (Table II). 
 
c) One hundred and seventy four decisions that appear to have been based on cost-effectiveness 
did not have available north-east quadrant ICERs.  For 39 of these decisions, cost-utility 
analysis was not undertaken, although another form of economic evaluation was done (e.g. 
cost-effectiveness analysis calculating the cost per life-year gained).  A further 36 decisions 
ŵĂĚĞ ďƌŽĂĚ ƌĞĨĞƌĞŶĐĞƐ ƚŽ ƚŚĞ ĐŽŵŵŝƚƚĞĞ ?Ɛ ũƵĚŐĞŵĞŶƚƐ ĂďŽƵƚĐŽƐƚ-effectiveness but no 
specific ICERs were quoted or identified; this included statements that the IZ “ĂƉƉƌŽĂĐŚĞƐ
ŝŶĨŝŶŝƚǇ ?ŽƌǁĂƐ  “ůŝŬĞůǇ ƚŽďĞĐŽƐƚ-ĞĨĨĞĐƚŝǀĞ ? ? Seventeen decisions were based on cost/QALY 
ICERs that were not available for analysis (e.g. because they were commercial in confidence, 
or the guidance document was unavailable).  Thirty-three decisions were rejected as 
treatment was dominated by its comparator, while 31 were recommended as treatment 
dominated. Six decisions had ICERs in the south-west quadrant, of which one was rejected.  
The decisions based on cost-effectiveness that lacked available north-east quadrant cost/QALY 
tended to be published about four years earlier than those included in regression analyses 
(p<0.001) and were less likely to be STAs (p<0.001) or only treatments (p<0.001). 
Among the 510 decisions with available north-east quadrant ICERs, ICERs differed significantly 
between recommended and rejected decisions (p<0.001; Table III).  Exploratory data analysis also 
demonstrated that the proportion of decisions rejected by NICE increases substantially with ICER 
(particularly at ~£27,500 and ~£47,500/QALY), although there are numerous exceptions (Figure 4).  
 
 
Notes: ĞĐŝƐŝŽŶƐĂƌĞƌĂŶŬĞĚďǇ/Z ?ǁŝƚŚE/ĚĞĐŝƐŝŽŶƐƚŽ ‘ƌĞĐŽŵŵĞŶĚ ?ƐŚŽǁŶŝŶďůƵĞĂŶĚƚŽ ‘ƌĞũĞĐƚ ?ƐŚŽǁŶŝŶƌĞĚ ?&Žƌ
clarity, only the first five datasets of randomly-sampled ICERs are shown. 
Figure 4. Impact of ICER ranking on recommendations
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Table II. Characteristics of included decisions 
Variable All decisions No due to lack 
of evidence 
Clinical grounds Based on cost-effectiveness but 
no available NE quadrant 
cost/QALY 
Included in regression analyses: 
NE quadrant ICER available 
NICE decision No Yes No Yes No Yes 
Total no. decisions 763 70 28 63 68 106 141 287 
Mean ICER (SD) £28,189 
(£52,463) 
N/A N/A N/A N/A N/A £66,974 
(£84,310) 
£17,028 
(£17,517) 
% of 
ICERs 
(n/N) 
A? ? ? ? ? ? ? ? ?Y>z 43% (182/428) N/A N/A N/A N/A N/A 11% (15/141) 58% (167/287) 
£20-£30,000/ 
QALY 
14% (61/428) N/A N/A N/A N/A N/A 8% (11/141) 17% (50/287) 
A? ? ? ? ? ? ? ? ?Y>z 43% (184/428) N/A N/A N/A N/A N/A 81% (114/141) 24% (70/287) 
Total_pts_in_RCTs (SD) 3,402 (6,681) 680 (1,474) 1,502 (2,227) 1,965 (2,829) 3,817 (5,048) 2,861 (4,924) 3,108 (5,754) 4,812 (8,938) 
% Only_treatment (n/N) 3% (25/763) 6% (4/70) 18% (5/28) 3% (2/63) 0% (0/68) 0% (0/106) 
 
5% (7/141) 2% (7/287) 
% Children (n/N) 10% (74/763) 7% (5/70) 14% (4/28) 27% (17/63) 13% (9/68) 11% (12/106) 4% (5/141) 8% (22/287) 
% Pt_group_sub (n/N) 96% (730/763) 94% (66/70) 96% (27/28) 97% (61/63) 90% (61/68) 91% (96/106) 99% (139/141) 98% (280/287) 
Date (SD): years since Mar 
2000 
5.8 (3.3) 5.7 (3.1) 3.1 (2.0) 3.9 (2.4) 4.8 (3.3) 3.0 (2.5) 6.3 (3.1) 6.5 (3.1) 
Severity (SD): DALY weight 0.241 (0.110) 0.241 (0.119) 0.222 (0.114) 0.230 (0.091) 0.223 (0.106) 0.240 (0.113) 0.259 (0.097) 0.246 (0.114) 
% STA (n/N) 19% (144/763) 16% (11/70) 0% (0/28) 6% (4/63) 8% (5/68) 9% (10/106) 34% (48/141) 23% (66/287) 
% PSA (n/N) 63% (479/763) 47% (33/70) 29% (8/28) 57% (36/63) 49% (34/68) 33% (35/106) 66% (93/141) 77% (221/287) 
% Orphan (n/N) 5% (36/763) 4% (3/70) 0% (0/28) 0% (0/63) 1% (1/68) 1% (1/106) 9% (13/141) 6% (18/287) 
No_SRs (SD) 0.9 (2.5) 0.6 (2.8) 2.5 (4.1) 1.2 (3.0) 0.7 (1.7) 1.1 (2.2) 0.7 (1.8) 0.8 (2.5) 
No_obs_studies (SD) 2.0 (7.8) 3.6 (11.0) 9.4 (20.6) 1.2 (4.8) 1.4 (6.0) 2.2 (9.1) 1.4 (5.5) 1.5 (5.2) 
ICER_range (SD) £33,641 
(£134,021) 
N/A N/A N/A N/A N/A £97,683 
(£235,107) 
£9,133 
(£17,920) 
% Innovative (n/N) 15% (116/763) 9% (6/70) 4% (1/28) 8% (5/63) 17% (11/68) 14% (14/106) 19% (27/141) 18% (52/287) 
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Table III.  Prediction accuracy and model fit for Models 1-5 
Model name % 
correctly 
classified 
Sensitivity Specificity Mean 
AIC* 
Mean 
adjusted 
pseudo-R
2
* 
Cost/QALY at which 
probability of a NICE 
recommendation is 50% 
 ? ? ?й ? ? ?й ? ? 
1: ICER, Date, Total_pts_in_RCTs, Children, Only_treatment, 
Pt_group_sub & Severity  
82.46% 94.02% 58.90% -338 
 
0.336 
 
£43,356 (£58,793, 
£27,936) 
2:  ICER  Total_pts_in_RCTs, Only_treatment, Children, Pt_Group_Sub, 
Date, STA, Orphan, No_SRs, No_obs_studies, PSA, Cancer, Cardiovascular, 
Infectious, Musculoskeletal, Respiratory, ICER_range, Innovative (model 
with best prediction accuracy after Stage B) 
84.67% 93.18% 67.35% -265 
 
0.417 
 
£39,479 (£53,616, 
£25,358) 
3: ICER, Musculoskeletal, Respiratory, Cancer (variables significant in at 
least one analysis in Stages A&B) 
83.50% 93.74% 62.66% -332 
 
0.362 
 
£42,391 (£57,021, 
£27,781) 
4: ICER  Total_RCTs Mean_pts_per_RCT Only_treatmentifICER>30k 
Children Pt_group_sub ICER*Pt_group_sub [11 dummies for publication 
year] STA PSA Orphan No_SRs No_obs_studies Cancer Cardiovascular 
Infectious Musculoskeletal Respiratory ICER_range Innovative (model 
with best prediction accuracy after Stage C) 
87.18% 94.24% 72.80% -217 
 
0.447 
 
£39,417 (£51,754, 
£27,047) 
5: ICER only 82.00% 93.30% 58.99% -357 0.332 £43,949 (£60,377, 
£27,548) 
* Mean AIC and pseudo-R
2
 are shown for illustration only. Models were estimated separately for each of 100 datasets with ICERs sampled from the list of those relevant to each decision; the 
log-pseudo-likelihood for the model (LLM) and for the constant-only model (LL0) was averaged over the 100 datasets.  AIC was calculated manually from the mean log-likelihood as -2LLM + 2k 
and adjusted pseudo-R
2
 was calculated as 1-(LLM/LL0)*((n-1)/(n-k)), where k=number of model parameters (explanatory variables plus constant) and n=number of decisions.  
 ?dŚĞŵĞĂŶǀĂůƵĞƐĨŽƌĂůůŽƚŚĞƌmodel parameters were multiplied by model coefficients to calculate the predicted log-odds of a positive NICE recommendation at a range of ICER values; the 
ƌĞƐƵůƚŝŶŐĨŝŐƵƌĞƐǁĞƌĞƵƐĞĚƚŽŝĚĞŶƚŝĨǇƚŚĞ/ZĂƚǁŚŝĐŚƚŚĞƉƌŽďĂďŝůŝƚǇŽĨE/ƐĂǇŝŶŐ ‘ǇĞƐ ?ĞƋƵĂůled 25%, 50% and 75%. 
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5.1. Factors affecting NICE decisions 
Model 1 evaluated the impact of the seven variables considered most likely to influence NICE 
decision-making (Tables III and IV).  This model fitted the data well (mean adjusted pseudo-R
2
=0.34) 
and correctly classified 82.5% of NICE decisions (Table II).  As expected, the ICER had a significant 
effect on NICE decisions, with every £1,000 increase in the ICER reducing the odds of NICE 
recommending the technology by 6.9% (95% CI: 4.3%, 9.4%; p<0.001; Table IV).  
 
Table IV.  Coefficients from Models 1 and 2 
Variable Odds ratio (95% CI) 
Model 1 Model 2 
ICER  ? ? ? ? ? ?Ɛ ? 0.931 (0.906, 0.957)** 0.925 (0.893, 0.959)** 
Total_pts_in_RCTs 1.000 (1.000, 1.000) 1.000 (1.000, 1.000) 
Only_treatment (dummy) 2.499 (0.457, 13.667) 4.279 (0.696, 26.297) 
Children (dummy) 2.390 (0.312, 18.308) 4.097 (0.384, 43.740) 
Pt_group_sub (dummy) 0.962 (0.097, 9.571) 1.119 (0.132, 9.498) 
Date (years) 1.062 (0.943, 1.195) 1.134 (0.947, 1.357) 
Severity (DALY weights) 0.397 (0.025, 6.362) - 
STA (dummy) - 0.426 (0.185, 0.975)** 
PSA (dummy) - 0.443 (0.155, 1.271) 
Orphan (dummy) - 0.630 (0.144, 2.759) 
No_SRs  - 1.024 (0.928, 1.130) 
No_obs_studies - 1.121 (0.991, 1.268)* 
Cancer (dummy) - 3.063 (1.119, 8.383)** 
Cardiovascular (dummy) - 0.837 (0.291, 2.401) 
Infectious (dummy) - 2.209 (0.359, 13.594) 
Musculoskeletal (dummy) - 5.732 (1.615, 20.343)** 
Respiratory (dummy) - 0.288 (0.089, 0.927)** 
/Z YƌĂŶŐĞ ? ? ? ? ? ?Ɛ ? - 1.000 (1.000, 1.000)* 
Innovative (dummy) - 1.701 (0.656, 4.411) 
* p<0.10; ** p<0.05 
 
However, clinical evidence, having no alternative treatments, paediatric population, patient group 
submission, ĚŝƐĞĂƐĞƐĞǀĞƌŝƚǇĂŶĚĚĂƚĞŚĂĚŶŽƐŝŐŶŝĨŝĐĂŶƚĞĨĨĞĐƚŽŶE/ĚĞĐŝƐŝŽŶƐ ?ƉA? ? ?29; Table IV).  
As hypothesised, there were trends suggesting that decisions concerning children and those with no 
alternative treatments have a higher chance of being recommended by NICE (Table IV).  However, 
the impact of additional clinical evidence was negligible and treatments for more severe diseases 
and those supported by patient group submissions had a non-significantly lower chance of being 
recommended (p=0.53), contrary to our hypothesis.  Nonetheless, omitting any variable from the 
model other than disease severity slightly reduced prediction accuracy, suggesting that these 
variables may help explain some NICE decisions.  
 
Prediction accuracy was slightly improved by taking account of 12 of the 17 additional variables 
evaluated in Stage B (Table A1): the appraisal process (STA vs. multiple technology appraisal, MTA); 
whether the analysis included probabilistic sensitivity analysis (PSA); orphan status; the number of 
systematic reviews and non-randomised studies considered; the range of ICERs; and certain 
diseases.  Model 2 (Table IV) therefore included these variables, in addition to all variables from 
Model 1 other than severity (which was omitted to improve prediction accuracy).  Model 2 correctly 
classified 84.67% of NICE decisions which represents a small improvement on Model 1 (Table II). 
 
Model 2 suggested that interventions classed as innovative (p=0.29), those with more systematic 
reviews (p=0.67) or non-randomised studies (p=0.07) and those with a smaller range of ICERs 
(p=0.07) were non-significantly more likely to be recommended (Table III).  However, contrary to our 
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expectations, decisions with PSA (p=0.13) and those on orphan drugs (p=0.46) were non-significantly 
less likely to be recommended.  Appraisals conducted through the STA process were also found to be 
51% (95% CI: -9%, 78%) more likely to be rejected by NICE than MTAs, although this result was not 
significant (p=0.083).  
 
There were also marked differences in the probability of NICE rejection between diseases.  The odds 
of a positive NICE recommendation were 5.7-fold higher (p=0.007; 95% CI: 1.6, 20.3) for 
musculoskeletal disease interventions, 3.1-fold higher (p=0.029; 95% CI: 1.1, 8.4) for decisions 
concerning treatment, prevention or diagnosis of cancer and 71% lower (p=0.037, 95% CI: 7%, 91%) 
for interventions for respiratory disease. Model 4 gave similar findings. 
 
These findings were largely confirmed by Model 3, which included only statistically significant 
variables (ICER, musculoskeletal disease, cancer and respiratory disease), although omitting the non-
significant variables reduced prediction accuracy to 83.5% and reduced the magnitude of the 
coefficients for each of the three diseases, such that cancer and musculoskeletal disease had no 
statistically significant effect at the 5% level (pA? ? ? ? ? ?).
  
The impact of end of life criteria was evaluated in a subset of appraisals published after these criteria 
were introduced in January 2009 (NICE, 2009).  This suggested that decisions meeting the end of life 
criteria were 3.4-fold more likely (p=0.15, 95% CI: 0.64, 17.9) to be recommended by NICE than 
those that did not meet the criteria.  Within this group of decisions, taking account of end of life 
criteria improved prediction accuracy from 84.23% with Model 1 to 85.12%.  A sensitivity analysis 
found that allowing for the identity of the committee making NICE recommendations slightly 
improved prediction accuracy, although there were no statistically significant differences between 
committees.  
 
However, overall the impact of additional variables on prediction accuracy was very small, with no 
variable increasing prediction accuracy by more than one percentage point.  Indeed, omitting all 
variables except the ICER correctly classified 82% of NICE decisions (Table III, Model 5).  By contrast, 
omitting the ICER from Model 2 suggests that the other variables in isolation would correctly classify 
only 73.1% of NICE decisions.  
 
5.2. Relationship between ICER and probability of NICE recommendation 
Coefficients from the five models were used to estimate how the probability of NICE rejection varied 
with ICER, holding all other parameters at mean values (Figure 5, Table III).  Model 1 suggested that 
a treatment with an ICER of £43,356 would have a 50% chance of a positive NICE recommendation, 
holding all other parameters at mean values.  This model also predicted that NICE would 
recommend 25% of products with an ICER of £62,253 and 75% with an ICER of £27,935. The ICER at 
which the average product had a 50% chance of rejection decreased as additional variables were 
taken into account, from £43,949 for Model 5 (which considered only the ICER) to £39,417 for Model 
4 (Table III, Figure 5).  The interaction between ICER and patient group submission also increased the 
gradient for Model 4, such that the probability of NICE rejection increases over a narrow range of 
ICERs. 
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Figure 5.  Predicted probability of NICE rejections at different ICER values for Models 1-5, holding all other 
variables at mean levels 
 
However, although the choice of model had relatively little effect on the relationship between ICER 
and recommendation when other variables were held at their mean value, varying the value of other 
variables often produced substantial shifts in the curve.  For example, for Model 4, the ICER at which 
the probability of NICE ƐĂǇŝŶŐ ‘ǇĞƐ ?was 50% was £20,356/QALY for respiratory disease, £37,950 for 
cardiovascular disease, £46,082 for cancer, £49,292 for infectious disease, £55,512 for 
musculoskeletal disease, and £32,263 for other diseases.  For any given ICER point estimate, having 
uncertainty around the ICER such that the ICER could plausibly be £10,000 higher or lower than the 
point estimate decreased the 50% point to £43,516/QALY, compared with £48,014 for decisions with 
only one plausible ICER. 
 
The decisions that were poorly predicted by our models were generally rejected due to substantial 
uncertainty, or included statements within the guidance suggesting that the committee believed the 
ICER to be at the top or bottom of the stated range (see Appendix).  This is supported by a sensitivity 
analysis using the minimum ICER for all recommended decisions and the minimum ICER for all 
rejected decisions correctly classified 93.0% of decisions, which may suggest that around two-thirds 
of the decisions poorly classified by our model may be due to difficulties identifying the ICER that 
ĚƌŽǀĞƚŚĞĐŽŵŵŝƚƚĞĞ ?ƐĚĞĐŝƐŝŽŶďĂƐĞĚŽŶƐĞĐŽŶĚĂƌǇĚĂƚĂ ?
 
5.3. ,ĂƐE/ ?ƐƚŚƌĞƐŚŽůĚĐŚĂŶŐĞĚŽǀĞƌƚŝŵĞ ?
Model 1 suggested that publication date had no significant effect on NICE decisions (p=0.31) and 
estimated that the odds of a positive NICE recommendation increased by 6% (95% CI: -5%, 19%) per 
year between 2000 and 2011.  Similarly, although inflation will also affect the real value of any 
ceiling ratio, inflating ICERs to 2011/12 values using the HCHS pay and prices index (Curtis, 2012) 
reduced prediction accuracy.  We examined alternative specifications of publication time to assess 
the impact on prediction accuracy (Appendix), although no statistically significant temporal trends 
were observed.  
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6. Discussion 
6.1.  Implications for understanding how NICE weighs up benefits and costs 
Our analyses demonstrate that cost-effectiveness is the principal determinant of most NICE 
decisions and that the probability of rejection increases significantly with increasing ICER.  The 
finding was robust to extensive sensitivity analyses and modelling approaches. 
 
The relationship between ICER and the probability of NICE rejection appears to follow a sigmoid 
curve with points of inflexion.  However, the data do not appear to support the £5,000-
£15,000/QALY and £25,000-£35,000/QALY inflexion points proposed by Rawlins and Culyer (2004). 
EĞŝƚŚĞƌĚŽŽƵƌƌĞƐƵůƚƐƐƵƉƉŽƌƚE/ ?ƐƐƚĂƚĞĚƚŚƌĞƐŚŽůĚƌĂŶŐĞ ? Based on NICE statements, we would 
expect that for ICERs under £20,000/QALY, a recommendation would be odds-on; above 
£30,000/QALY it would be odds-against; and that the odds switch from on to against somewhere in 
between.  We estimate that in practice the ICER at which the probability switches from more-likely-
to-accept to more-likely-to-reject is between £39,000 and £44,000: well above the stated £20,000-
£30,000 range.  
 
It is informative to compare our estimates with emerging evidence on what the cost-effectiveness 
threshold should be.  Although NICE formally subscribes to an opportunity cost definition of the 
threshold and has advocated research into that (Claxton et al, 2013; Appleby et al 2009), it has also 
advocated research into the social value of a QALY (Baker et al, 2010).  Our results clearly show that, 
in practice, NICE often recommends technologies with ICERs that are well above the opportunity 
cost estimated by Claxton et al (2013), but somewhat closer to the social value of a QALY (Baker et 
al, 2010).  
 
6.2. Temporal trends and impact of other factors 
Although allowing for temporal trends improved model performance, time had no significant effect 
on NICE decisions and the relationship we estimate between cost-effectiveness and NICE decisions 
between 1999 and 2011 is remarkably similar to that reported by Devlin and Parkin (2004) for the 
years 1999-2002, despite the many changes in NHS budgets, prices and productivity in the 
intervening seven years.  Although the models reported here treat ICERs in nominal terms, inflation 
must have affected the prices and costs embodied in the ICERs in the appraisals conducted over this 
10-year period; yet inflation-adjusting ICERs reduced model performance. 
 
The single factor other than cost-effectiveness that emerged from our analyses as exerting a 
significant effect on decisions is the type of disease that the technology is intended to prevent, 
diagnose or treat.  NICE rejections were significantly less likely for cancer and musculoskeletal 
disease, but significantly more likely for respiratory disease.  It is unclear whether such trends reflect 
a causative relationship between disease and NICE decisions (e.g. driven by political priorities, the 
shadow price of a QALY and/or willingness to pay), or whether it reflects selection of topics or other 
characteristics of the decisions within each disease area.  The finding for cancer was clearest before 
the End of Life Guidance was introduced, with NICE recommending 75% (49/65) of cancer decisions 
before January 2009, vs. 46% (24/52) after; however, the end of life guidance may have simply 
formalised something that NICE was already taking into account. 
 
Other than certain diseases, no variables other than cost-effectiveness significantly predicted NICE 
decisions.  However, the relevance of statistical significance is unclear when the sample includes the 
whole 'population' of NICE decisions published before 2012. Furthermore, our descriptive analysis 
suggests that 21% (161/763) of decisions are based on clinical considerations and lack of clinical 
evidence, without considering cost-effectiveness.  It is also possible that NICE took account of other 
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factors that cannot easily be defined or quantified, were not explicitly noted in the Guidance, or 
were one-off considerations specific to particular decisions.  The influence of additional factors not 
detected in our analysis would have biased upwards our estimate of the ICER at which the 
probability of rejection is 50%.  Furthermore, several factors that NICE says influence its decisions 
are difficult empirically to define and measure.  For example, although severity is said to influence 
NICE decisions (Rawlins et al, 2009), NICE Guidance does not state whether the condition was 
considered to be  ‘ƐĞǀĞƌĞ ? ĂŶĚ ŝŶ ƚhĞ ĂďƐĞŶĐĞ ŽĨ Ă ƉƌĞĐŝƐĞ ĚĞĨŝŶŝƚŝŽŶ ŽĨ  ‘ƐĞǀĞƌŝƚǇ ? ? ŝƚ ŝƐ ĚĨĨŝĐƵůƚ ĨŽƌ
researchers to judge ex post which technologies would be deemed to fall into that category; the 
measure we used (mean DALY weight across ICD chapters) may not adequately represent the way 
NICE committees consider severity ?   ‘/ŶŶŽǀĂƚŝŽŶ ? ƉƌĞƐĞŶƚƐ Ă ƐŝŵŝůĂƌ ĐŚĂůůĞŶŐĞ, as do other criteria 
(e.g. disadvantaged populations) that we were not able to explore.  E/ ?Ɛ ĂƉƉƌĂŝƐĂů ƉƌŽĐĞƐƐ ŝƐ
intended to reflect and incorporate multiple criteria, but the effect on decisions of criteria other 
than cost-effectiveness is not readily detectable; it could therefore be argued that NICE should be 
more transparent about the criteria being used and the importance attached to these (Devlin and 
Sussex 2010).  However, others would argue that a deliberative process without pre-defined weights 
is needed to consider the evidence and make complex decisions (Culyer and Lomas, 2006). 
 
Budget impact, population size and media noise might arguably be relevant to understanding and 
explaining NICE decisions but were not included in our analysis.  One argument for excluding budget 
impact is that NICE is not meant to take that into account.  We would have liked to test this 
hypothesis rather than assuming that it has no impact.  However, budget impact estimates are only 
recorded for whole TAs based on the patient subgroups for which treatment was recommended; 
estimating the net budget impact for each sub-decision would be a substantial task, beyond the 
scope of this project.  
 
Although we have explored measures of clinical evidence and uncertainty, this was not entirely 
satisfactory and remains to be properly captured both conceptually and empirically.  Devlin and 
Parkin (2004) expressed similar reservations regarding the variable they intended to capture the 
range of the ICERs.  We considered, but rejected, the possibility of using confidence intervals or cost-
effectiveness acceptability curves estimated using PSA.  Although PSA is now more common, 
modelling this variable would require us to exclude all decisions where PSA was not undertaken. 
Furthermore, using the probability that treatment is cost-effective at a given ceiling ratio would 
require value judgements regarding the appropriate ceiling ratio.  
 
6.3. Conclusions 
Our analysis uses a larger number of decisions than any past analysis of HTA decisions and explores 
the impact of a wide range of potential predictors.  We find that cost-effectiveness is the major 
driver of NICE decisions and correctly predicts 82% of decisions.  No other factors besides the type of 
condition had a significant effect on NICE decisions, although allowing for clinical evidence, 
alternative treatments, paediatric population, patient group involvement, publication date, type of 
process (STA versus MTA), orphan status, innovation and uncertainty improved prediction accuracy 
somewhat.  Our results show that NICE frequently recommends technologies with ICERs 
considerably higher than its stated £20,000-£30,000/QALY threshold range.  However, the analysis 
relied upon judgements about which ICER(s) were taken into account in each NICE decision and our 
ĐŽŶĐůƵƐŝŽŶƐĂƌĞďĂƐĞĚŽŶƚŚĞĂƐƐƵŵƉƚŝŽŶƚŚĂƚǁĞŚĂǀĞŝĚĞŶƚŝĨŝĞĚƚŚĞ “ĐŽƌƌĞĐƚ ?ŵŽĚĞů.  Further work 
is required to explore the impact of uncertainty, severity, innovation and equity on NICE decisions 
and to explore the structure of NICE decision-making using sequential models. 
18  CHE Research Paper 93 
 
References  
Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. 2009. Searching for cost-effectiveness 
thresholds in the NHS.  Soc Sci Med  91: 239-245. 
 
Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto 
Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; SVQ Research Team. 2010. 
Weighting and valuing quality adjusted life years: preliminary results from the social value of a QALY 
project. Health Technology Assessment 14:1-162. 
 
Briggs A, Fenn P. 1998. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness 
plane. Health Economics 7:723-40. 
 
Carlin JB, Galati JC, Royston P. 2008. A new framework for managing and analyzing multiply imputed 
data in Stata. Stata Journal 8:49-67. 
 
Claxton K, Martin S, Soares M, Rice, N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. 2013. 
Methods for the estimation of the NICE cost effectiveness threshold. CHE Research Paper 81   
http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP81_methods_estimati
on_NICE_costeffectiveness_threshold_revised.pdf  Accessed 8th November 2013. 
 
Copas JB. 1983. Regression, prediction and shrinkage. J Royal Statist Soc B 45 : 311-354. 
 
Curtis L. 2012. Unit Costs of Health and Social Care 2012. Canterbury, UK: PSSRU Personal Social 
Services Research Unit. Available at: www.pssru.ac.uk/project-pages/unit-costs/2012/. Accessed 30
th
 
July 2013. 
 
Culyer AJ. 2006 NICE's use of cost-effectiveness as an exemplar of a deliberative process. Health 
Economics, Policy and Law 1: 299-318. 
 
Culyer, AJ, Lomas, J, 2006. Deliberative processes and evidence-informed decision-making in health 
care  W do they work and how might we know? Evidence and Policy 2: 357- 371. 
 
Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher, M, Brazier J. 2007. 
Searching for a threshold, not setting one: The role of the National Institute for Health and Clinical 
Excellence. Journal of Health Services Research and Policy 12: 56 - 58. 
 
Culyer A. 2009. Deliberative Processes in Decisions about Health Care Technologies: Combining 
Different Types of Evidence, Values, Algorithms and People. OHE Briefing no 48. London: Office of 
Health Economics. 
 
Dakin HA, Devlin NJ, Odeyemi IA. 2006. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE 
decision-making. Health Policy 77:352-67. 
 
Devlin N,Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors 
influence its decisions? A binary choice analysis. Health Economics 13:437-52. 
 
Devlin N , Sussex J. 2011. Incorporating Multiple Criteria in HTA: Methods and Processes. London: 
Office of Health Economics.  
The influence of cost-effectiveness and other factors on NICE decisions  19 
 
 
Harris AH, Hill SR, Chin G, Li JJ, Walkom E. 2008. The role of value for money in public insurance 
coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 
28:713 W722. 
 
Hirth RA, Chernew ME, Miller E, Fendrick M, Weissert WG.2000. Willingness to pay for a quality-
adjusted life year. Med Decis Making 20:332-42. 
 
Littlejohns P, Rawlins M. 2009. ^ŽĐŝĂůǀĂůƵĞũƵĚŐĞŵĞŶƚƐ PŝŵƉůĞŵĞŶƚŝŶŐƚŚĞĐŝƚŝǌĞŶ ?ƐĐŽƵŶĐŝůƌĞƉŽƌƚƐ ?
Chapter 12 in: Littlejohns P, Rawlins M (eds) Patients, the Public and Priorities in Health Care. 
Radcliffe.  
 
Linley WG,Hughes DA. 2012. Reimbursement decisions of the All Wales Medicines Strategy Group: 
influence of policy and clinical and economic factors. Pharmacoeconomics 30:779-94. 
 
McCabe M, Claxton K, Culyer AJ.2008. The NICE cost-effectiveness threshold. What it is and what 
that means. Pharmacoeconomics 26:733-44. 
 
Mason AR, Drummond MF.2009. Public funding of new cancer drugs: Is NICE getting nastier? 
European Journal of Cancer 45:1188-92. 
 
Mason H, Jones-Less A, Donaldson C. 2009. Modelling the monetary value of a QALY: a new 
approach based on UK data. Health Economics 18: 933-50. 
 
Mshelia I, White R, Mukke S, 2013. An investigation into the key drivers influencing the decision 
making of the Scottish Medicines Consortium. Value in Health 2013 16: A264 
 
National Institute for Health and Clinical Excellence. 2010. E/ƐĂǇƐ “ǇĞƐ ?ƚŽŽǀĞƌ ? ?A?ŽĨ
treatments. Available at: 
www.nice.org.uk/newsroom/news/NICEsaysYes.jsp?domedia=1&mid=E99E7EDB-19B9-E0B5-
D4FCD1EB8398B6DD. Accessed 13th September 2013. 
 
National Institute for Health and Clinical Excellence. 2009. Appraising life extending, end of life 
treatments. Supplementary advice to the Appraisal Committees. Available at: 
www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp?domedia=1&mid=88
ACDAE5-19B9-E0B5-D422589714A8EC6D. Accessed 13th September 2013. 
 
National Institute for Health and Clinical Excellence. 2008. Social value judgements: Principles for the 
development of NICE guidance. Second Edition. Available at: 
http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf. Accessed 13th November 2010. 
 
National Institute for Health and Clinical Excellence. 2013. Guide to the methods of technology 
appraisal. Available at: 
http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed 
3rd October 2013. 
 
National Institute for Health and Clinical Excellence. 2005. Social value judgements: Principles for the 
development of NICE guidance. Available at: http://www.nice.org.uk.  
 
National Institute for Health and Clinical Excellence. 2004. Guide to the methods of technology 
appraisal. Available at: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed 18th 
November 2010. 
20  CHE Research Paper 93 
 
K ?EĞŝůů W ? Devlin N. 2010. Ŷ ĂŶĂůǇƐŝƐ ŽĨ E/ ?Ɛ ƌĞƐƚƌŝĐƚĞĚ  ?Žƌ  ‘ŽƉƚŝŵŝƐĞĚ ? ? ĚĞĐŝƐŝŽŶƐ ?  
Pharmacoeconomics 28 : 987-993. 
 
Rawlins M, Culyer A J. 2004. National Institute for Clinical Excellence and its value judgements.  
British Medical Journal 329: 224-227. 
 
Rawlins M, Barnett D, Stevens A. 2010. WŚĂƌŵĂĐŽĞĐŽŶŽŵŝĐƐ PE/ ?ƐĂƉƉƌŽĂĐŚƚŽĚĞĐŝƐŝŽŶŵĂŬŝŶŐ ?
British Journal of Clinical Pharmacology 70: 346-349.  
 
Rosen S. 1974. Hedonic prices and implicit markets: product differentiation in pure competition. The 
Journal of Political Economy 82, 34-55.  
 
StataCorp. 2011. Stata: Release 12. Statistical Software (http://www.stata.com). College Station, TX: 
StataCorp LP.  
 
Stafinski T, Menon D, Davis C, McCabe C. 2011. Role of centralized review processes for making 
reimbursement decisions on new health technologies in Europe. ClinicoEconomics and Outcomes 
Research 3: 117 W186. 
 
Tappenden P, Brazier J, Ratcliffe J, Chilcott J. 2007 A stated preference binary choice experiment to 
explore NICE decision making. Pharmacoeconomics 25:685-93. 
 
White I R, Royston P, Wood, A.M. 2011. Multiple imputation using chained equations: Issues and 
guidance for practice. Stat Med 30: 377-399. 
 
WHO, World Health Organisation. 2004. Global Burden of Disease 2004 Update: Disability Weights 
For Diseases and Conditions. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed 
26
th
 July 2013. 
 
Williams I, Bryan S, McIver S. 2007. How should cost-effectiveness analysis be used in health 
technology coverage decisions? Evidence from the National Institute for Health and Clinical 
Excellence approach.  J Health Serv Res Policy 12: 73-9. 
The influence of cost-effectiveness and other factors on NICE decisions  21 
 
 
Appendix: Modelling strategy and additional coefficients 
 
Principles used to guide our selection of the relevant ICERs:  
x Include only cost per QALY gained; alternative cost-effectiveness measures (e.g. cost per life-
year gained) were excluded;  
x Where there were several ICERs reported for alternative comparators, use the ICER relative to 
the comparator that NICE considered most appropriate; if this is not specified in the Guidance, 
use the ICER relative to next most effective treatment on the cost-effectiveness frontier. 
x ǆĐůƵĚĞ /ZƐ ƚŚĂƚ ƚŚĞ  ‘ĐŽŶƐŝĚĞƌĂƚŝŽŶ ŽĨ ĞǀŝĚĞŶĐĞ ? ƐĞĐƚŝŽŶ ŽĨ ƚŚĞ 'ƵŝĚĂŶĐĞ ƐƉĞĐŝĨŝĐĂůůǇ
ŝŶĚŝĐĂƚĞĚƚŚĂƚE/ĚŝĚŶŽƚ ‘ďĞůŝĞǀĞ ? ? 
x Where the main ICER is a range rather than a point, capture the limits of that range, but do 
not include the wider range of ICERs that may be generated from full sensitivity analysis. 
 
Exploring the reasons for NICE recommendations for outliers 
In general, the decisions that were poorly predicted by one of the five models were also poorly 
predicted by others. The rationale for the NICE decision was reviewed for 22 decisions where NICE 
rejected the technology, but models predicted that the probability of a positive recommendation 
was >0.62 (odds >0.5). In nine of these decisions the modelling was used in deliberations but 
ƵŶĐĞƌƚĂŝŶƚǇ ůĞĚ ƚŽ Ă ũƵĚŐĞŵĞŶƚ ƚŚĂƚ ƚŚĞ  “ƚƌƵĞ ? /Z ǁĂƐ ƐƵďƐƚĂŶƚŝĂůůǇ ŚŝŐŚĞƌ ? ǁŚŝĐŚ ǁĂƐ ŶŽƚ
quantified in the guidance.  In five instances, although a low ICER was reported, there were other 
treatment options with lower ICERs.  Four further decisions had a wide range of ICER values, and 
comments in the guidance document implied that the higher ICERs may be plausible.   Models 
predicted that the probability of a positive recommendation was <0.38 (odds <-0.5) in >66 of the 100 
datasets for five decisions where NICE recommended the technology. In three of these cases, the 
committee made non-quantified adjustments to the reported ICER which implied that treatment 
was cost-effective for the subgroup for which it was recommended.  One decision had a wide range 
of ICERs, although statements in the guidance suggested that the committee believed that the real 
ICER was in the lower end of this range.   The final case was an early appraisal where NICE explicitly 
stated that an ICER in the range of £34,000 to £43,500 was cost-effective.  
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Table A1 Variables included in Stage B 
Variable name Coding Definition Justification 
STA 1=STA 
0=MTA 
Whether the appraisal was conducted via the single technology appraisal 
(STA) process or the multiple technology appraisal (MTA) process.* 
Mason and Drummond (2009) suggested 
that NICE may be more likely to say no in 
STAs. 
Pharmaceutical 1=Pharmaceutical 
0=other technology 
Whether the technology was a drug. Based on the HTAinSite product type 
field HTAinSite.* 
May reflect degree of stakeholder 
involvement. 
Orphan 1=orphan drug 
0=not an orphan drug 
Whether the technology has been granted orphan status by the European 
Medicines Agency (EMEA).* 
 “E/ĐŽŶƐŝĚĞƌƐƚŚĂƚŝƚƐŚŽƵůĚĞǀĂůƵĂƚĞĚƌƵŐƐ
ƚŽƚƌĞĂƚƌĂƌĞĐŽŶĚŝƚŝŽŶƐ ?ŬŶŽǁŶĂƐ ‘ŽƌƉŚĂŶ
ĚƌƵŐƐ ? ?ŝŶƚŚĞƐĂŵĞǁĂǇĂƐĂŶǇŽƚŚĞƌ
ƚƌĞĂƚŵĞŶƚ ? ?E/2008; Littlejohns and 
Rawlins, 2009). 
No_SRs Numeric: number of reviews Number of systematic reviews mentioned in the Guidance and assessment 
report.* 
Additional measure of clinical evidence. 
No_obs_studies Numeric: number of studies Number of non-randomised studies mentioned in the Guidance and 
assessment report.* 
Additional measure of clinical evidence. 
PSA 1=PSA conducted 
0= PSA not conducted 
Whether the uncertainty around the economic evaluation was quantified 
using probabilistic sensitivity analysis (PSA).* 
Significant predictor of AWMSG decisions 
(Linley & Hughes 2012). 
Broader_perspective 1= considered broader costs 
0= NHS only 
Whether personal and societal costs were considered in addition to NHS 
cost (consideration included discussion in the text as well as inclusion in 
quantitative analyses).* 
Reflects consideration of additional costs or 
savings not captured in the base case ICER. 
Disease Series of 8 dummy variables 
equal to 1 if concerned that 
disease 
ĂĐŚĚĞĐŝƐŝŽŶǁĂƐĐůĂƐƐĞĚĂƐŽŶĞĚŝƐĞĂƐĞĐĂƚĞŐŽƌǇďĂƐĞĚŽŶƚŚĞ “DĂŝŶ
ĚŝƐĞĂƐĞĐĂƚĞŐŽƌǇ ?ĨŝĞůĚǁŝƚŚŝŶ,dŝŶ^ŝƚĞ ? ?ŝƐĞĂƐĞĐĂƚĞŐŽƌŝĞƐǁŝƚh less than 
20 decisions with ICERs were omitted. As result, decisions were categorised 
into cancer, cardiovascular, central nervous system, endocrine, infectious 
disease, mental health, musculoskeletal, respiratory and other. 
May reflect variations in clinical need, 
severity or importance of rule of rescue 
between diseases, as well as different 
political priorities. 
Innovative 1= classed as innovative 
0= classed as non-innovative 
Any molecule launched within two years of appraisal AND in an ATC4 class 
that was created within 5 years of the appraisal. Non-pharmaceutical 
interventions were classed as non-innovative. 
For interventions with ICERs above 
£20,000/QALY, the committee will take 
ĂĐĐŽƵŶƚŽĨ “ŝŶŶŽǀĂƚŝŽŶƚŚĂƚĂĚĚƐ
demonstrable and distinct substantial 
benefits that may not have been adequately 
ĐĂƉƚƵƌĞĚŝŶƚŚĞŵĞĂƐƵƌĞŵĞŶƚŽĨŚĞĂůƚŚŐĂŝŶ ?
(NICE 2008). 
ICER_range Numeric: difference between 
minimum and maximum ICERs 
For decisions with more than one north-east quadrant ICER identified as 
driving the decision, this equalled the difference between the highest and 
lowest of such ICERs. Range was set to 0 for decisions with only 1 ICER. 
For interventions with ICERs above 
 ? ? ? ? ? ? ? ?Y>z ?E/ǁŝůůďĞ “ĐĂƵƚŝŽƵƐĂďŽƵƚ
recommending a technology when they are 
less cerƚĂŝŶĂďŽƵƚƚŚĞ/ZƐ ? ?E/2008). 
* Data taken from HTAinSite (www.htainsite.com).  
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Methods of sensitivity analysis 
The following analyses varying the specification of variables from the basic model were evaluated in 
Stage C: 
 
x Replacing the numeric ICER variable with two dummies (CERbetween20and30k and 
NotCosteffectiveat30kRc) indicating what band the ICER falls into. The hypothesis here is that 
if NICE based their decisions purely on whether or not the ICER was above or below the 
threshold, then this model should fit as well as the base case model. 
x Linear spline model: adding in two additional ICER terms as well as the ICER variable. One is 
equal to the ICER if the ICER is above £20,000 and zero if the ICER is below £20,000. Another is 
equal to the ICER if the ICER is above £30,000 and zero if it is below. This allows for the fact 
that the wording in the Social Value judgments document implies that NICE is most sensitive 
to ICER value if the ICER is in the 20-30k region and insensitive to ICER value below 20k. 
x Natural log of the ICER. 
x ICER adjusted to allow for inflation to 2011/12 values based on the pay and prices index 
(Curtis 2012). 
x Replacing Total_pts_inRCTs with two variables: total number of RCTs and the mean patient 
numbers in each reported RCT. 
x Replacing the Only_treatment variable with three interaction terms, which were evaluated 
since this variable is expected to only be taken into account if the ICER is >20k and is expected 
to be more important if the ICER>30k. 
o onlytreatment20k= Costeffectiveat20kRc* only_treatment (dropped) 
o onlytreatment20_30k= CERbetween20and30k * only_treatment (dropped) 
o onlytreatment30k= NotCosteffectiveat30kRc * only_treatment 
x Replacing the children variable with three interaction terms: 
o Children20k= Costeffectiveat20kRc * Children (dropped) 
o Children20_30k= CERbetween20and30k * Children (dropped) 
o Children30k= NotCosteffectiveat30kRc * Children 
x Adding an interaction between Pt_group_sub and ICER 
x Adding an interaction between Date and ICER interaction term  
x Adding a Date squared variable to allow for non-linear effect of date 
x Replacing the numeric Date variable with 3 dummies indicating whether the appraisal was:  
o Published between December 2005 and June 2008, while the first edition of the 
social value judgements document (NICE 2005) was in force. 
o Published after July 2008 when the latest social value judgements document (NICE 
2008) was published 
x Replacing the numeric Date variable with 11 dummies indicating the year of publication. 
x Replacing the numeric Date variable with a dummy indicating whether or not the appraisal 
was published after (or at the same time as) the first STA appraisal was published. 
x Adding an interaction between STA and ICER: explores whether ICERs are interpreted 
differently if they come from an STA rather than an MTA. 
24  CHE Research Paper 93 
 
Sensitivity analyses conducted on Model 4: 
 
x Adding in five dummy variables indicating which of the six committees evaluated the decision. 
x Adding in five dummy variables indicating committee, in addition to five interactions between 
committee and ICER. 
x Probit model (not logit) 
x No clustering 
x Random effects analysis to evaluate the impact of clustering by committee as well as 
clustering by appraisal  
x Random effects on appraisal (rather than clustering) 
x Fixed effects on appraisal (rather than clustering) 
x Replacing the ICER variable and all variables derived from it with each of the following in turn: 
o Mean across al ICERs identified as driving the decision 
o Midpoint between minimum and maximum ICER of those driving the decision 
o Minimum ICER of those driving the decision 
o Maximum ICER of those driving the decision 
o Using the maximum ICER for decisions that were rejected by NICE and the minimum 
ICER in the list for decisions that were recommended. 
 
Results of Stages C and D 
Variable specification was varied within Stage C, with the specification of each variable that had 
highest prediction accuracy being selected for inclusion within Model 4. This model correctly 
predicted 87.18% of NICE decisions. This analysis suggested that RCT evidence was best considered 
as an additive relationship between the total number of trials and the average size (rather than as 
the product of these two), although neither variable had a significant effect on NICE decisions (Table 
A2). Each additional RCT increased the odds of a positive NICE recommendation by 1.2% (p=0.54), 
while increasing the size of the average RCT by one patient decreased the odds by 0.008% (p=0.183). 
These coefficients are similar to those reported previously (Dakin et al, 2006), although our previous 
study found the number of RCTs to exert a statistically significant effect. Stage C modelling also 
suggested that a lack of alternative treatments may only affect NICE decision-making for decisions 
with ICERs above £30,000/QALY and suggested that prediction accuracy is improved by adding an 
interaction term between the ICER and patient group submissions, such that patient group 
submissions have greater impact for decisions with high ICERs. 
 
As a sensitivity analysis (Stage D), we also evaluated the impact of committee on NICE decisions, by 
categorising appraisals into six categories based on the chairperson of the committee that made the 
recommendation. This suggested that adding committee variables into Model 4 improved prediction 
accuracy, although there were no statistically significant differences between committees. 
 
Using the mean of the relevant ICERs or the midpoint between the highest and lowest ICERs for 
those decisions with moe than two relevant ICERs rather than using the simulation approach 
increased the proportion of decisions correctly classified by Model 4. This may suggest that when 
faced with several equally plausible ICER values, NICE (or individual committee members) base 
decisions on the mean or midpoint of the available ICERs.  Although the illustration of the 
probabilistic threshold presented by Rawlins (2004) suggested that NICE consider ICERs on a 
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logarithmic scale, taking the natural logarithm of the ICER reduced prediction accuracy, which may 
suggest that the NICE committees consider ICERs on a natural scale. 
 
Table A2: Coefficients for Model 4. 
Variable Variable definition Odds ratio (95% CI): Model 4 
ICER  ? ? ? ? ? ?Ɛ ? See Table I 0.858 (0.775, 0.951)** 
Total_RCTs Alternative specification of RCT evidence. 
Number of randomised controlled trials 
(RCTs) evaluating intervention in this 
population* (including commercial in 
confidence trials*). 
1.012 (0.974, 1.052) 
Mean_pts_per_RCT Alternative specification of RCT evidence. 
Mean number of patients in each fully 
reported RCT.* 
1.000 (1.000, 1.000) 
Only_treatment_ifICER>30k Dummy equal to 1 if the decision has an ICER 
above £30,000/QALY and has no alternative 
treatments (zero otherwise) 
13.198 (0.945, 184.340)* 
Children See Table I 4.274 (0.325, 56.142) 
Pt_group_sub See Table I 0.403(0.004, 37.486) 
ICER*Pt_group_sub  Interaction term: product of ICER and 
Pt_group_sub 
1.067 (0.965, 1.181) 
2001-2 Dummy variables indicating the year of 
guidance publication (base year: 2000-1) 
10.117 (0.039, 2616.590) 
2002-3 0.352 (0.041, 3.050) 
2003-4 0.077(0.008, 0.697)** 
2004-5 0.164 (0.008, 3.562) 
2005-6 0.172 (0.014, 2.173) 
2006-7 0.517 (0.068, 3.907) 
2007-8 1.035 (0.119, 9.025) 
2008-9 0.369 (0.050, 2.697) 
2009-10 0.790 (0.074, 8.407) 
2010-11 1.241 (0.139, 11.123) 
2011-12 0.358 (0.037, 3.493) 
STA  See Table I 0.410 (0.156, 1.083)* 
PSA See Table I 0.611 (0.222, 1.684) 
Orphan See Table I 0.733 (0.147, 3.667) 
No_SRs  See Table I 1.103 (0.892, 1.365) 
No_obs_studies See Table I 1.143 (0.981, 1.331 )* 
Cancer See Table I 3.417 (1.116, 10.465)** 
Cardiovascular See Table I 1.658 (0.434, 6.335) 
Infectious See Table I 4.532 (0.582, 35.306) 
Musculoskeletal See Table I 7.889 (1.509, 41.247)** 
Respiratory See Table I 0.347 (0.103, 1.172)* 
/Z YƌĂŶŐĞ ? ? ? ? ? ?Ɛ ? See Table I 1.000 (1.000, 1.000)** 
Innovation See Table I 1.965 (0.687 , 5.616) 
* p<0.1; ** p<0.05 
 
Replacing the ICER variable with dummy variables suggested that decisions with ICERs above 
£30,000/QALY (p<0.001) and those with ICERs between £20,000 and £30,000/QALY (p=0.003) were 
significantly less likely to be recommended than those with ICERs below £20,000/QALY. However, 
replacing the numeric ICER variable with dummies reduced prediction accuracy for Model 2, which 
suggests that although the magnitude of the ICER does affect the odds of NICE rejection, fixed 
thresholds of £20,000 and £30,000/QALY explain a large proportion of NICE decision-making. 
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Allowing for non-linear effects of date by including a publication date squared variable reduced 
prediction accuracy. However, replacing the publication date variable with dummy variables for the 
year the appraisal was published increased prediction accuracy; this analysis suggested that the 
ĐŚĂŶĐĞ ŽĨ E/ ƐĂǇŝŶŐ  ‘ǇĞƐ ? ŵĂǇ ŚĂǀĞ ĚĞĐƌĞĂƐĞĚ ďĞƚǁĞĞŶ ? ? ? ?-1 and 2003-4 and risen between 
2003-4 and 2011-12, although the odds of NICE ƐĂǇŝŶŐ  ‘ǇĞƐ ?were significantly different from the 
odds in 2000-12 only in 2003-4 (Table A2, Figure A1). We also investigated whether NICE decision-
making changed after NICE published its first Social Value Judgements document in November 2005 
or after those documents ĂŶĚƚŚĞĚĞƐĐƌŝƉƚŝŽŶŽĨE/ ?ƐƐƚĂƚĞĚƚŚƌĞƐŚŽůĚǁĞƌĞƌĞǀŝƐĞĚŝŶ ? ? ? ? ?E/, 
2005; 2008). Replacing the date variable with dummy variables suggested that the odds of NICE 
recommending a treatment were non-significantly lower after June 2008 than before November 
2005 (p=0.12) or between November 2005 and June 2008 (p=0.12). A further analysis found that 
decisions published after (or at the same time as) the first STA appraisal were non-significantly more 
likely to be recommended than those published earlier (p=0.07). Although we might expect a change 
in the discount rates recommended by NICE to affect ICERs, we found that neither the odds of NICE 
decisions nor the coefficient for the ICER changed significantly after the 2004 Methods Guide 
introducing the new discount rates was published (NICE 2004). 
 
 
Figure A1. Changes in the odds of NICE recommendation over time 
 
